Drugs / BAY1003803
last change Oct 2017 re-read 2 minutes ago

BAY1003803

Developed for
psoriasis
Investigated by
Bayer

Trials 2 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02936492 Oct 2016 → Apr 2017 psoriasis Bayer Terminated No outcome recorded
Phase 1 NCT02940002 Oct 2016 → Jan 2017 psoriasis Bayer Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BAY1003803 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02940002
1

NCT02936492

Route Topical “BAY1003803 0.1% lipophilic cream (on plaque and healthy skin)” NCT02940002